Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say

Insulet (PODD) reported $569 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 28.8%. EPS of $1.02 for the same period compares to $0.73 a year ago.The reported revenue represents a surprise of +4.96% over the Zacks Consensus Estimate of $542.11 million. With the consensus EPS estimate being $0.81, the EPS surprise was +25.93%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Insulet performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- International Omnipod: $152.40 million versus the six-analyst average estimate of $144.78 million. The reported number represents a year-over-year change of +32.2%. Revenue- U.S. Omnipod: $401.70 million versus $389.50 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +26.4% change. Revenue- Total Omnipod: $554.10 million compared to the $534.28 million average estimate based on six analysts. The reported number represents a change of +28% year over year. Revenue- Drug Delivery: $14.90 million versus the six-analyst average estimate of $7.37 million. The reported number represents a year-over-year change of +71.3%. View all Key Company Metrics for Insulet here>>>Shares of Insulet have returned -0.2% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Insulet Corporation (PODD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks